Michael Fossel Michael is President of Telocyte

February 20, 2018

Aging and Disease: 1.3 – Aging, What it IS

What IS aging?

An explanation of aging must account for all cells, all organisms, and – if we are candid – all of biology and isn’t merely entropy. Prior posts defined our boundaries: what we must include – and exclude. We know that we cannot simply point to entropy, wash our hands of any further discussion, and walk away with our eyes closed. Likewise, an honest explanation can’t simply consider humans and a few common mammals but ignore the entire gamut of Earth’s biology.

So, what IS aging? As a start, we might acknowledge that life has been on Earth for more than four billion years and during that entire time, life has resisted entropy. This serves as an excellent starting point: life might be defined as the ability to maintain itself in the face of entropy. In that case, we might rough out our initial definition: aging is the gradual failure of maintenance in the face of entropy.

We miss the point, however, unless we realize that aging is an active, dynamic process. Aging is not simply a matter of a failure of maintenance in the passive sense. To use an analogy, if entropy were an escalator carrying us downwards, then it is not the only process involved. It is countered by cell maintenance, which is precisely like walking upwards on the same escalator (see Figure 1.3a). Young cells are entirely capable, as are germ cells and many other cells, of indefinitely maintaining their position at the top of the escalator. Entropy and maintenance are equally balanced. Older cells, however, have a subtle (and sometimes not so subtle) imbalance, in which maintenance is less than entropy.

As aging occurs, the problem is not that the escalator (entropy) carries us downwards, but that we are no longer walking upwards (maintenance) at the same rate as the escalator. To view aging as the descending escalator alone is to miss the essential point of biology: life remains on this planet because cells and organisms “walk upwards” and maintain themselves indefinitely in the face of being “carried downwards” by entropy. The process is a dynamic balancing act. To explain aging, it is not enough to cite the escalator, but requires that we explain why maintenance fails, and then only in certain cells and at certain times, while remaining functional in other cells and at other times. Aging is far from universal. A valid explanation of aging must account for why aging occurs in some cases yet does not occur in other cases.

 

Aging is not the escalator but is a combination of two forces: entropy carrying cells into dysfunction and maintenance ensuring that cells remain functional. Aging occurs only when maintenance is down-regulated. If maintenance is not down-regulated, then the cells and the organism do not age. Aging cells, such as many somatic cells, age because they down-regulate maintenance. “Immortal” cells, such as germ cells, do no age because they do not down-regulate maintenance.

We might try an analogy to see where it takes us, comparing biological aging to “aging” in a car. We could say that aging in a car is not simply what happens as the car undergoes weathering and degradation over time. Rather, car aging would be what happens if we fail to maintain the car on a regular and detailed basis. There are exceptional antique cars that have been in active use longer than most human lifetimes, but they are in excellent shape not because they had better parts (i.e., have the right genes) or were made by a better manufacturer (i.e., are part of the right species), but because they were maintained scrupulously and carefully on an almost daily basis by generations of owners. Such cars are oiled, painted, repaired, realigned, and cared for on an almost daily basis, compared to most cars that are lucky to be cared for annually. The critical difference is not the chronological age of the car nor the amount of wear-and-tear, but the frequency and excellence of their maintenance. Given frequent and excellent maintenance, sufficient to keep up with entropy, a car can last indefinitely, while with sloppy and merely annual maintenance, cars typically last only a few years before “aging” takes them off the road.

In a sense, organisms are no different: the degree of aging is not just a matter of time or entropy, but of the quality and frequency of maintenance. Likewise, aging is not purely a matter of which genes or what species pertain to that organism. Rather, aging is a matter of the rate of repair and recycling within cells, that is, maintenance in the face of entropy.
It’s not the genes, it’s the gene expression.

Let’s use another example, that of water recycling. Every molecule of water that you ingest has been recycled endlessly, but the speed and efficiency of that recycling determines the quantity and quality of the water you drink. Imagine that we plan a trip to Mars. If the average astronaut needs 2 liters per day and 4 astronauts are on a 2.5-year roundtrip to Mars, we might calculate that we need to bring 7 tons of water. But that (incorrectly) assumes no recycling. We can get by on a lot less water, depending on how we recycle. The amount we need to bring with us depends not only on the amount the astronauts use daily, but on the quality and rate of recycling (from urine, for example). The faster the recycling, the less water we need to carry along. The better the quality of our recycling, the longer we can stay healthy.

In a “young” and efficient cell, we recycle molecular pools rapidly and effectively. In an old cell, however, the rate and effectiveness of the recycling decreases. The analogy for our Mars trip would be slower recycling, along with an increasing percent of contaminants that are not being removed in our water recycling unit. The outcome, whether in aging cells or a mission to Mars, is gradually increasing dysfunction. Aging cells no longer function normally (as when they were young cells) and our sickening astronauts no longer function normally either (as when they started out on Earth).
As another example, you oversee a huge office building with multiple daily customers and hundreds of employees. Every night, your cleaning crew comes through, mopping the solid floors, vacuuming the carpets, cleaning the windows, and (when necessary) repainting the walls. Maintenance is frequent and excellent; as a result, the building always looks new (i.e., young). Now let’s radically cut back on your maintenance budget. Instead of daily maintenance, the carpets are vacuumed once every two weeks, the floors are mopped once a month, the windows are cleaned once a year, and repainting occurs once a decade. The resulting problem is not due to the amount of dirt (the entropy), nor the quality of the vacuum, the mop, the washer fluids, or the paint (think of these as the quality of your genes). The problem isn’t the dirt nor is it the cleaning crew, but the rate of maintenance. The outcome is that your building looks dirty and is increasingly incapable of attracting clients or customers – or for that matter, incapable of retaining employees. This parallels the changes in aging cells: the genes (the cleaning products) are excellent and the quality of repair (the cleaning staff) are both excellent, but the frequency of maintenance is too low to maintain the quality of the building. In aging cells, molecular turnover is too slow to keep up with entropic change.

This same analogy could be applied to home repairs, garden weeding, or professional education. The problem is not entropy, but our ability to resist entropy and maintain function. Aging occurs because cell maintenance becomes slower. The quality of gene expression is fine, but molecular turnover (see figure 1.3b) – the “recycling rate” – declines. This effect is subtle but pervasive and the result is increasing dysfunction. This concept – the failure of maintenance to keep up with entropy — is not only central to aging but can account for all of aging and in all organisms, whether at the genetic level, the cellular level, the tissue level, or the clinical outcome – age-related disease.

Aging is a dynamic process, in which entropy begins to gain as maintenance processes become gradually down-regulated.

In subsequent posts, we will explore the detailed mathematics of this change, reviewing the formula and the primary variables, letting us see the remarkable results that occur in terms of denatured molecules and cellular dysfunction. For now, however, let’s look at a few specific clinical examples in human aging, all of which we’ll return to in later posts, when we consider age-related diseases in great detail.

In human skin, between cells, we see changes in collagen and elastin (among dozens of other proteins) as we age. Many people mistakenly assume that these changes are a simple, static accumulation of damage over a lifetime, but these changes are anything but static. These molecules are in dynamic equilibrium, in which the molecules (and their complex structures) are constantly being produced (anabolism) and broken down (catabolism). The overall rate of recycling (the overall metabolism) is high in young skin, with the result that at any given time, most molecules are undamaged and functional (and relatively new). This rate slows with aging, however, with the result that molecules remain longer before being “recycled” and the percentage of damaged and dysfunctional molecules rises, slowly but inexorably. In old skin, molecules “sit around” too long before being recycled. Old skin isn’t old because of damage, but because the rate of maintenance becomes slower and slower. Naïve cosmetic attempts to “replace” skin collagen, elastin, moisture, or other molecules fail because they are transient interventions. By analogy, these cosmetic interventions would be like – in the case of our old, dirty office building – suggesting that we will send in one person, one night, to clean one window pane. Even if you notice a small, transient improvement, the problem isn’t resolved by bringing in one person for a single visit, it requires that we resume having the entire cleaning crew come in every night. Intervening in skin aging is not a matter of providing a few molecules, but of increasing the rate of turnover of all the molecules.

The same problem occurs in aging bones. The problem that lies at the heart of osteoporosis is not “low calcium”, but the rate at which we turnover our bony matrix. Looking solely at calcium as one example, osteoporosis not a static problem (add calcium), but a dynamic problem (increase the rate of calcium turnover). Moving our attention from minerals to cells, young bone is constantly being taken apart (by osteoclasts) and rebuilt (by osteoblasts). The result is continual remodeling (recycling) and repair. Bone turnover is a continual process that slows with age. Young fractures heal quickly and thoroughly. In old bone, however, the rate of remodeling falls steadily, and rebuilding falls slightly behind. The result is that we have decreased matrix, decreased mineralization, decreased bone mass, and an increasing risk of fractures. The fundamental problem underlying osteoporosis is not “a loss of bone mineral density”, but an inability to maintain bony replacement. It’s not the calcium or the phosphorous, but the osteocytes themselves. Loss of bone mineralization is a symptom, not the cause of osteoporosis.

A more tragic and more fatal example is Alzheimer’s disease. Until relatively recently, the leading pathological target was beta amyloid, a molecule which (like tau proteins and other candidates) shows increasing damage and denaturation (plaques in the case of amyloid) in older patients, especially in patients with Alzheimer’s disease. Again, however, amyloid is not a static molecule that is produced, sits around, and slowly denatures over a lifetime. Amyloid is continually produced and continually broken down, but the rate of recycling falls as we age. The result is that the percentage of damaged amyloid (plaque) rises with age, solely because the rate of turnover is slowing down. As we will see, the cells that bind, internalize, and breakdown this molecule become slower as we age. To address Alzheimer’s, we don’t need to remove amyloid or prevent its production, we need to increase the rate of turnover. Beta amyloid plaques are a symptom, not the cause of Alzheimer’s disease.

Wherever we look — an aging cell, an aging tissue, or an aging organism – we see that aging is not a static, linear loss of function due to entropy. Rather, aging is a dynamic process in which the rate of recycling – whether of intracellular enzymes, extracellular proteins, aging cells, or aging tissues – becomes slower as cells senesce. Aging is a programmed failure of maintenance at all biological levels. This is equally true of DNA repair, mitochondrial function, lipid membranes, proteins, and everything else we can measure in an aging system.

We’ve had a glimpse at the core of aging. Let’s explore an overview of how changes in gene expression translate into cell dysfunction, tissue failure, clinical disease, and aging itself.

Next time: Aging, the Overview

February 13, 2018

Aging and Disease: 1.2 – Aging, What We Have to Explain

Our understanding is limited by our vision.

If we look locally, our understanding is merely local; if we look globally, our understanding becomes more global; and if we look at our entire universe, then our understanding will be universal. When we attempt to understand our world, we often start with what we know best: our own, local, provincial view of the world around us, and this limits our understanding, particularly of the wider world beyond our local horizon.

Trying to explain the shape of our world, I look at the ground around me and – perhaps not surprisingly – conclude that the world is probably flat. After all, it looks flat locally. Trying to understand the heavens, I look up at the sky around me and – perhaps not surprisingly – conclude that the sun circles the earth. After all, the sun appears to circle over me locally. Trying to understand our physical reality, I look at everyday objects and – perhaps not surprisingly – conclude that “classical physics” accounts for my universe. After all, classical physics accounts for typical objects that are around me locally. As long as we merely look around, look up, and look at quotidian objects, these explanations appear sufficient.

But it is only when we look beyond our purely local neighborhood – when we move beyond our provincial viewpoint, when we give up our simple preconceptions – that can we begin to understand reality. Taking a broader view, we discover that the Earth is round, that the sun is the center of our local star system, and that quantum and relativity physics are a minimum starting point in trying to account for our physical universe.

To truly understand requires that we step back from our parochial, day-to-day, common way of seeing world and open our minds to a much wider view of reality. We need to look at the broader view, the larger universe, the unexpected, the uncommon, or in the case of modern physics, the extremely small and the extremely fast. Time, mass, energy, and other concepts may become oddly elusive and surprisingly complicated, but our new understanding, once achieved, is a lot closer to reality than the simple ideas we get from restricting our vision to the mere commonplace of Newtonian physics. This is true of for branch of science, and for human knowledge generally.

The wider we cast our intellectual nets, the more accurately we understand our world.

To understand aging demands a wide net. If our knowledge of aging is restricted to watching our friends and neighbors age, then our resulting view of aging is necessarily naïve and charmingly unrealistic. If we expand our horizons slightly, to include dogs, cats, livestock, and other mammals, then we have a marginally better view of aging. But even if we realize that different species age at different rates, our understanding is only marginally less naive. To truly understand aging, we need to look at all of biology. We need to look at all species (not just common mammals), all diseases (e.g., the progerias and age-related diseases in all animals), all types of organisms (e.g., multicellular and unicellular organims, since some multicellular organisms don’t age and some unicellular organisms do age), all types of cell within organisms (since somatic cells age, germ cells don’t, and stem cells appear to lie in between the two extremes), and all the cellular components of cells. In short, to understand aging – both what aging is and what aging isn’t – we need to look at all life, all cells, and all biological processes.

Only then, can we begin understand aging.

To open our minds and examine the entire spectrum of aging – so that we can begin to understand what aging is and how to frame a consistent concept of “aging” in the first place – let’s contrast the small sample we would examine in the narrowest, common view of aging with the huge set of biological phenomena we must examine if we want to gain comprehensive and accurate view of aging, a view that allows us to truly understand aging.

The narrow view, the most common stance in considering aging, examines aging as we encounter it in normal humans (such as people we know or people we see in the media) and in normal animals (generally pets, such as dogs and cats, and for some people, domesticated animals, such as horses, cattle, pigs, goats, etc.). This narrow view leaves out almost all species found on our planet. This sample is insufficient to make any accurate statements about the aging process, with the result that most people believe that “everything ages”, “aging is just wear and tear”, and “nothing can be done about aging”. Given the narrow set of data, none of these conclusions are surpring, but then it’s equally unsurprising that all of these conclusion are mistaken.

A broad view has a lot more to take into consideration (see Figure 1), which is (admittedly) an awful lot of work. The categories that we need to include may help us see how broad an accurate and comprehensive view has to be. We need to examine and compare aging:

  1. Among all different organisms,
  2. Within each type of organism,
  3. Among all different cell types, and
  4. Within each type of cell.

 

Lets look at these categories in a bit more detail.

When we look at different organisms, we can’t stop at humans (or even just mammals). We have to account for aging (and non-aging) in all multicellular organisms, including plants, lobsters, hydra, naked rats, bats, and everything else. And not only do we need to look at all multicellular organisms, we also need to account for aging (and non-aging) in all unicellular organisms, including bacteria, yeast, amoebae, and everything else. In short, we need to consider every species.

When we look within organisms, we need to account for all age-related diseases (and any lack of age-related diseases or age-related changes) within organisms. Diseases will include all human (a species that is only one tiny example, but that happens to be dear to all of us) age-related diseases, such as Alzheimer’s disease and all the other CNS age-related diseases, arterial aging (including coronary artery disease, strokes, aneurysms, peripheral vascular disease, cogestive heart failure, etc.), ostoarthritis, osteoporosis, immune system aging, skin aging, renal aging, etc. But we can’t stop there by any means. In addition to age-related diseases within an organism, we need to look at aging changes (and non-aging) whether they are seen as diseaeses or not, for example graying hair, wrinkles, endocrine changes, myastenia, and hundreds of other systemic changes in the aging organism.

When we look at different cells, we need to account for the fact that some cells (e.g., the germ cell lines, including ova and sperm) within multicellular organisms don’t age, while other cells in those same organims (e.g., most somatic cells) do age, and some cells (e.g., stem cells) appear to be intermediate between germ and somatic cells in their aging changes.

When we look within cells, we need to account for a wild assortment of age-related changes in the cells that age, while accounting for the fact that other cells may show no such changes, even in the same species and the same organism. In cells that age – cells that senesce – we need to account for telomere shortening, changes in gene expression, methylation (and other epigenetic changes), a decline in DNA repair (including all four “families” of repair enzymes), mitochondrial changes (including the efficacy of aerobic metabolism enzymes deriving from the nucleus, leakier mitochondrial lipid membranes, increases in ROS production per unit of ATP, etc.), decreased turnover of proteins (enzymatic, structural, and other proteins), decreased turnover of other intracellular and extracellular molecules (lipids, sugars, proteins, and mixed types of molecules, such as glycoproteins, etc.), increased accumulation of denatured molecules, etc. The list is almost innumerable and still growing annually.

If we are truly to understand aging, we cannot look merely at aging humans and a few aging mammals, then close our minds and wave our hands about “wear and tear”. If we are to understand aging accurately and with sophistication, then we must not only look at a broader picture, but the entire picture. In short, to understand aging, we must stand back all the way in both time and space, and look at all of biology.

To understand aging, we must understand life.

February 7, 2018

Aging and Disease: 1.1 – Aging, What it Isn’t

Filed under: Aging diseases,Alzheimer's disease,mitochondria — Tags: , , , — webmaster @ 9:29 am

It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so.

– Mark Twain

Twain was right, particularly when it comes to the aging process: there is a lot we think we “know for sure that just ain’t so”. For example, most people (without even thinking about it and with a fair amount of naïve hand-waving) assume that all organisms age and equate aging with entropy. In other words, they think that “aging is just wear-and-tear”. We assume that aging “just happens” and that nothing can be done about it. After all, we all get old, things fall apart, things rust, everything wears out, so what can you expect? But as with Twain’s remark, the trouble is that we are quite sure of ourselves and we what we think is completely obvious, turns out to be completely wrong. We are content to gloss over our faulty assumptions and move to faulty conclusions. It’s bad logic, bad science, and a bad way to intervene in the diseases of aging. Without thinking about it, we conclude that aging is as simple as our preconceptions, which turn out to be erroneous.

Aging isn’t simple and our preconceptions are wrong.

As with most concepts that we don’t examine meticulously, aging is a lot more complex than we realize. Aging isn’t just entropy, it isn’t just wear-and-tear, and it isn’t many things that people blithely believe it to be. Let’s look at a few examples that make us back up and reconsider how aging works. Let’s start with your cells, and then your mitochondria.

We could take any cell in your body, for example a skin cell on the back of your hand. How old is that skin cells? Since we shed perhaps 50 million skin cells every day, there’s a good chance that the cell we are thinking about is only a day or so old, or at least a day or so since the last cell division. But that last division was from a “mother” cell that was there before the cell division resulted in two “daughter” cells. So perhaps our skin cell, counting the age of the “mother” cell is a week or so old? But that “mother” cell, in turn, derived from a dividing cell that was there several weeks ago, backwards ad infinitum to the first cells that formed your body. In fact, every cell in your body is certainly as the whole body, so perhaps that skin cell is a few decades old. You might say that the skin cell has the same age that you see on your driver’s license. Except that your entire body is the result of a cell (ova) from your mother and a cell (sperm) from your father, and each of those cells was already a few decades old (or however old your parents were) when the sperm and ovum became “you” when they joined at fertilization. But, of course, your parent’s germ cells came from their parents, whose germ cells came from their parents, and we can trace that lineage of germ cells back to… Well, all the way back to the origin of life on Earth. So in a very real, very strictly accurate biological sense, every cell in your body is 3.5 billion years old.

But if we assume that aging is just entropy, then we have explain why that line of germ cells (that resulted in your entire body) didn’t undergo any entropy (i.e., didn’t age) for 3.5 billion years and yet your somatic cells are now undergoing entropy (i.e., aging) in your body and have been aging since you were born. Why do somatic cells suffer from entropy, if germ cells don’t? Does entropy only work in certain cells and not in others? Apparently so. And if that’s true, then we can’t just wave our hands and invoke entropy as the entire explanation, can we? We have to explain something more subtle and complicated: why entropy results in aging in some cases (the somatic cells in your body) but not in other cases (the line of 3.5 billion year-old germ cells that led up to you having a body in the first place). How interesting. So much for just invoking the concept of entropy and walking away satisfied.

Entropy almost certainly plays a key role in aging, but we can’t simply leave it at that. We need to think a bit harder. Sometimes entropy wins (your body and most of its cells age in a matter of decades) and sometimes entropy doesn’t appear to win at all (your germ cell line didn’t age for 3.5 billion years). Why sometimes and not other times?

One way that some people have tried to explain this is to invoke mitochondrial damage, but an almost identical problem surfaces in the case of mitochondrial entropy. Given the prevalence of aging explanations based on free radical theory (reactive oxygen species, etc.), mitochondrial dysfunction is an obvious suspect for an explanation of aging. We know that older mitochondria make more free radicals, leak more, and those free radicals aren’t scavenged as well, so perhaps all of aging is a mitochondrial problem? Perhaps entropy simply causes mitochondrial damage and that’s why we age. Perhaps entropy works by aging our mitchondria, right?

Except that mitochondrial entropy can’t explain aging either.

If aging were the result of “aging” mitochondria, damaged by entropy (high internal mitochondrial temperature, free radicals, loose protons and electrons, and a general accumulation of mitochondrial damage over time), then we are still left with an embarrassing conundrum. To understand the problem, let’s ask a simple question: how old are your mitochondria? Mitochondria divide fairly constantly, depending on the cell and its energy demands. In some cells (such as liver cells), with high energy demands, mitochondria are dividing all the time, in others with low energy demands, mitochondria divide much less frequently. On the other hand, since every mitochondria in every cell in your body derived from the mitochondria that were present in you as a fertilized zygote, we might reasonably say that your mitochondria are all the same age as your body, i.e., all of your mitochondria are a few decades old, and as time goes by, your mitochondria simply wear out, right?

Well, no.

Every mitochondria that you had as a fertilized zygote was derived from your mother’s ovum, which supplied all of your original mitochondria, so your mitochondria are as old as you are. Well, as old as you are plus as old as your mother was when you were conceieved. Oh, and plus the age of her mother and her mother and so on, ad infinitum back as far as the very first mitochondrial inclusion in the very first eukaryotes (or so). So every mitochondria in your body is about 1.5 billion years old and they’re doing pretty well for their age. But that means that if we want to blame aging entirely on mitochondrial dysfunction (and mitochondria surely play a major role in aging), we are still left with a conundrum. We have to explain why all of those dividing mitochondria (which were at least 1.5 billion years old) hadn’t aged for 1.5 billion years, and now all of your mitochondria are having significant problems after only a few decades. Why do your mitochondria suddenly start aging when they were doing so well for the last 1.5 billion years? The problem is that your mitochondria really do showing aging changes, but the mitochondra from your mother clearly didn’t until you came along. Worse yet, we have to explain both of these effects (aging and non-aging) simultaneously if we want to explain aging at all. How can we do both? We can’t simply wave our hands (again) and blame entropy unless we can simultanously explain why entropy works sometimes and in some cells (liver cells, for example), but entropy doesn’t work at other times and in other cells (the mitochondria in the germ cell line, for example). Again, why sometimes and not other times?

If entropy were an entirely sufficient explanation, they why does entropy age some cells (and some mitochondria) and not other cells (and other mitochondria)? If we restrict our explanation of aging solely to entropy, then we have a problem. We can’t just say that entropy does cause aging (because sometimes it doesn’t) nor can we say that entropy doesn’t cause aging (because sometimes it does). Entropy plays a role in aging, but not always.Why? What we have to do, if we really want to explain aging, is explain why entropy varies in biological systems. Sometimes entropy wins, sometimes it doesn’t.

Our preconception about entropy – wear-and-tear – as the sole cause for aging is a common misconception and not always noticed. It creates a subtle, but pervasive bias in our thinking about biolgy and aging. Even once we realize that entropy can’t explain all of cell or mitochondrial aging, we still find entropy creeping back into our thinking, but disguised under a different form. We tend to think of Alzheimer’s, for example, as what happens when beta amyloid, tau proteins, or mitochondria undergo entropy and cause neuronal death and clinical disease. We think of skin aging as what happens when collagen and elastin undergo entropy and cause wrinkles and aging skin. Some people blame aging on entropy of the endocrine system, concluding that all of aging comes about because of entropy in a gland or hormonal tissue. The fact that aging can occur in some organisms without endocrine systems (and that replacing hormones doesn’t stop aging) doesn’t change their misconception. But whatever guise it hides under, entropy by itself, cannot explain aging or age-related disease. There are too many odd things to explain, too many exceptions, too many cases where entropy explains one finding, but not another finding. Entropy can explain this cell, but not that cell. Entropy can explain this mitochondria, but not that mitochondria. Entropy simply can’t explain aging in toto. We have to dig a bit further.

Entropy, as an explanation of aging, only works if we close our eyes and ignore most of biology. As we’ll see in the next blog, there is a lot of biology that needs to be accounted for if we are going to explain how aging works. However we try to shoehorn entropy into being the entire explanation, aging cannot be entropy alone. As we will see, entropy does play a crucial role, but we cannot simply cite entropy, wave our hands, and say we understand aging. Aging is not entropy: aging is entropy plus something else, something subtle and complex, but something crucial to a complete understanding of aging.

As we will soon see, aging is entropy in the face of failing maintenance.

 

Next: 1.2 – Aging, What We Need to Explain

January 23, 2018

Aging and Disease: 0.1 – A Prologue

Aging and Disease

0.1 – A Prologue

Over the past 20 years, I have published numerous articles, chapters, and books explaining how aging and age-related disease work, as well as the potential for intervention in both aging and age-related disease. The first of these publications was Reversing Human Aging (1996), followed by my articles in JAMA (the Journal of the American Medical Association) in 1997 and 1998. Twenty years ago, it was my fervent hope that these initial forays, the first publications to ever describe not only how the aging process occurs, but the prospects for effective clinical intervention, would trigger interest, growing understanding, and clinical trials to cure age-related disease. Since then, I have published a what is still the only medical textbook on this topic (Cells, Aging, and Human Disease, 2004), as well as a more recently lauded book (The Telomerase Revolution, 2015) that explains aging and disease, as well as how we can intervene in both. While the reality of a clinical intervention has been slow to come to fruition, we now have the tools to accomplish those human trials and finally move into the clinic. In short, we now have the ability to intervene in aging and age-related disease.

Although we now have the tools, understanding has lagged a bit for most people. This knowledge and acceptance have been held back by any number of misconceptions, such as the idea that “telomeres fray and the chromosomes come apart” or that aging is controlled by telomere length (rather than the changes in telomere lengths). Academics have not been immune to these errors. For example, most current academic papers persist in measuring peripheral blood cell telomeres as though such cells were an adequate measure of tissue telomeres or in some way related to the most common age-related diseases. Peripheral telomeres are largely independent of the telomeres in our coronary arteries and in our brains and it is our arteries and our brains that cause most age-related deaths, not our white blood cells. The major problem, howevere, lies in understanding the subtlety of the aging process. Most people, even academics, researchers, and physicians, persist in seeing aging as mere entropy, when the reality is far more elusive and far more complex. Simplistic beliefs, faulty assumptions, and blindly-held premises are the blinders that have kept us powerless for so long.

It is time to tell the whole story.

While my time is not my own – I’d rather begin our upcoming human trials and demonstrate that we can cure Alzhiemer’s disease than merely talk about all of this – I will use this blog for a series of more than 30 mini-lectures that will take us all the way from “chromosomes to nursing homes”. We will start with an overview of aging itself, then focus in upon what actually happens in human cells as they undergo senesceence, then finally move downstream and look at how these senescent changes result in day-to-day human aging and age-relate disease. In so doing, when we discuss cell aging, we will get down into the nitty-gritty of ROS, mitochondria, gene expression, leaky membranes, scavenger molecules, molecular turnover, collagen, beta amyloid, mutations, gene repair, as well as the mathematics of all of this. Similarly, when we discuss human disease, we will get down into the basic pathology of cancer, atherosclerosis, Alzheimer’s, osteoporosis, osteoarthritis, and all “the heart-ache and the thousand natural shocks that flesh is heir to”. We will look at endothelial cells and subendothelial cells, glial cells and neurons, osteoclasts and osteoblasts, fibroblasts and keratinocytes, chondrocytes, and a host of other players whose failure results in what we commonly think of aging.

I hope that you’ll join me as we, slowly, carefully, unravel the mysteries of aging, the complexities of age-related disease, and the prospects for effective intervention.

December 1, 2017

Big Pharma: Still Looking for the Horse

About a century ago, in a small American town, the first automobile chugged to a stop in front of the general store, where a local man stared at the apparition in disbelief, then asked “where’s your horse?” A long explanation followed, involving internal combustion, pistons, gasoline, and driveshafts. The local listened politely but with growing frustration, then broke in on the explanation. “Look”, he said, “I get all that, but what I still want to know is ‘where is your horse?’”

About three hours ago, in a teleconference with a major global pharmaceutical company, I was invited to talk about telomerase therapy and why it might work for Alzheimer’s, since it doesn’t actually lower beta amyloid levels. I explained about senescent gene expression, dynamic protein pools whose recycling rates slow significantly, causing a secondary increase in amyloid plaques, tau tangles, and mitochondrial dysfunction. The pharmaceutical executive listened (not so politely) with growing frustration, then broke in on the explanation. “Look”, she said, “I get all that, but what I still want to know is how does telomerase lower beta amyloid levels?”

In short, she wanted to know where I had hidden the horse.

The global pharmaceutical company that invited me to talk with them had, earlier this year, given up on its experimental Alzheimer’s drug that aimed at lowering beta amyloid levels, since it had no effect on the clinical course. None. They have so far wasted several years and several hundred million dollars chasing after amyloid levels, and now (as judged by our conversation) they still intent on wasting more time and money chasing amyloid levels. We offered them a chance to ignore amyloid levels and simply correct the underlying problem. While not changing the amyloid levels, we can clean up the beta amyloid plaques, as well as the tau tangles, the mitochondrial dysfunction, and all the other biomarkers of Alzheimer’s. More importantly, we can almost certainly improve the clinical course and largely reverse the cognitive decline. In short, we have a new car in town.

As with so many other big pharmaceutical companies, this company is so focused on biomarkers that they can’t focus on what those markers imply in terms of the dynamic pathology and the altered protein turnover that underlies age-related disease, including Alzheimer’s disease. And we wonder why all the drug trials continue to fail. The executive who asked about amyloid levels is intelligent and experienced, but wedded to an outmoded model that has thus far shown no financial reward and – worse yet – no clinical validity. It doesn’t work. Yet this executive met with me as part of a group seeking innovative approaches to treating Alzheimer’s disease.

Their vision is that they are looking for innovation.

The reality is that they are still looking for the horse.

March 21, 2017

The Frustration of (Not) Curing Alzheimer’s

I am deeply frustrated by two plangent observations: 1) we squander scant resources in useless AD trials and 2) AD can easily be cured if we applied those same resources to useful AD trials. Applying our resources with insight, we will cure Alzheimer’s within two years.

The first frustration is that most pharmaceutical firms and biotech companies continue to beat their heads against the same wall, regardless of clinical results. Whether they attack beta amyloid, tau proteins, mitocondrial function, inflammation, or any other target, the results have been, without exception, complete clinical failures. To be clear, many studies can show that you can affect beta amyloid or other biomarkers of Alzheimer’s disease, but none of these studies show any effect on the clinical outcome. In the case of amyloid, it doesn’t matter whether you target production or the plaques themselves. Despite hundreds of millions of dollars, despite tens of thousands of patients, not one of these trials has ever shown clinical efficacy. Yet these same companies continue to not only run into walls, but remained convinced that if they can only run faster and hit the wall faster, they will somehow successfully breach the wall. They succeed only in creating headaches, accompanied by lost money, lost opportunities, and lost patients. The problem is not a lack of intelligence or ability. The researchers are – almost without exception – some of the most intelligent, well-educated, technically trained, and hard-working people I know. The irony is that they are some of the best 20th century minds I know. The problem, however, is that it is no longer the 20th century. If you refuse to adapt, refuse to change your paradigm, refuse to come into the 21st century, you will continue to get 20th century results and patients will continue to die of Alzheimer’s disease. Money and intelligence continues to be dumped into the same clichéed paradigm of pathology, as we aim at the wrong targets and misunderstand how Alzheimer’s works. And the result is… tragedy.

The second frustration is that we already know the right target and we already understand how Alzheimer’s disease works. We are entirely able to cure and prevent Alzheimer’s disease now. At Telocyte, we already have the initial resources we need to move ahead, but it is surprising how difficult it is for some people — wedded to 20th century concepts — to grasp the stunning potential, both clinically and financially of what we are about to do at Telocyte. We can not only reverse Alzheimer’s disease, but we can also cut the costs of health care while creating a stunningly successful biotech company in the process. We have the right tools, the right people, the right partners, and the sheer ability to take this through FDA trials. Already, we have several lead investors committed to our success. We are asking for a handful of additional investors, those who can see what the 21st century is capable of and who can understand why Telocyte is both the best clinical investment and the best financial investment in innovative medical care.

 

December 13, 2016

Telomeres: The Purloined Letter of Aging

     “What is only complex is mistaken (a not unusual error) for what is profound.”

                                                Edgar Allen Poe

 Edgar Allen Poe is still well-known for his poetry, he is less well-known for his detective stories. Some 170 years ago, his Parisian amateur detective, Dupin, was the conceptual forerunner for Sherlock Holmes, who made his London debut almost half a century later. Poe also made a series of observations that echo, even today, as we try to understand aging, age-related disease, and how we can cure them.

Poe’s detective pointed out that even intelligent, meticulous investigators are often oblivious to the obvious. The same can even be true of modern scientific investigators, who may focus so closely on their hard-won facts that the relationships between those facts – and their implications – are often overlooked. In aging research, for example, many investigators focus so intensely on genes, proteins, and small-molecular therapies, that they can miss the broader picture and miss an effective approach to curing the diseases of aging. Putting it simply, too often we focus our intellect, our education, and our strenuous effort on the “nouns”, but we entirely miss the “verbs”. We know the data, we fail to see what it means.

The intellect, the education, the dedication, and the funding are enormous, but our focus is off-target and the results, as expected, are futile. Truth, Poe tells us, is frequently overlooked, regardless of how intense our investigation. In describing such a case (in Poe’s case a policeman, in our case a scientist), Poe put it this way:

“… he erred continually by the very intensity of his investigations. He impaired his vision by holding the object too close. He might see, perhaps, one or two points with unusual clearness, but in so doing he, necessarily, lost sight of the matter as a whole. Thus there is such a thing as being too profound. Truth is not always in a well. In fact, as regards the more important knowledge, I do believe that she is invariably superficial.”

 As Poe suggest, we seek truth in the depth of a well in a valley, while truth is usually sitting in plain sight on the (easily visualized) mountain tops surrounding that valley. Such is the case with aging. It’s not that the truth is simple, for aging is far more complex than most of us give it credit for, but the truth is not found in the narrow details so much as it found in the overview of those details. The truth really is on the mountain tops, not in the bottom of a well, even when that well includes reams of data. It’s not the amount of data that is crucial, but the implications of that data. To give an example from clinical medicine, I may know everything about a patient’s fever, their hypotension, their abnormal white count, and their vomiting, but the numbers alone aren’t nearly as important as the realization that the patient has Ebola. Curing an Ebola infection cannot be relegated to lowering a fever, increasing the IV fluid, removing white cells, and given an anti-emetic. It’s not the individual therapies that cure Ebola, it’s the realization that you’re dealing with a viral infection and the use of a more general – and more effective – therapy, whether an antiviral or an immunization.

There is a parallel in understanding aging.

Treating the diseases of aging is not a matter of using individual therapies, but a matter of understanding the more profound relationships that change in aging cells. Until we do so, we will continue to fail when we try monoclonal antibodies for beta amyloid – as Eli Lilly finally realized with its Solanezumab trials – or merely attack tau proteins, mitochondrial changes, inflammation, or other targets. In each case, we have mistaken a plethora of data for a profundity of data. Only when we realize the actual complexity, the dynamic biological relationships, the profound effects of epigenetic changes, the role of telomeres as a therapeutic target, and that the fundamental pathology of aging and age-related diseases is rooted in cell senescence, only then will we — to our own vast and naïve surprise — discover that we can cure most of the diseases that still plague humankind.

 

November 15, 2016

Close to a Cure

We are now within two years of a cure for Alzheimer’s disease.

What a brash and disruptive claim! What hubris! Yet events are coming together, underlining a new and far more complete understanding of the disease, illuminating the cause, supporting the ability to intervene, safely and effectively. We finally see a way to intervene in the basic pathology, underlining the potential to both prevent and cure Alzheimer’s disease.

But why has it taken so long? Why was Alzheimer’s disease first defined 110 years ago, and yet remains totally beyond our ability to intervene even now? Why have all other approaches, whether those of big pharma or those of biotech, failed utterly? Why has not a single clinical trial shown any ability to change the progress of this frightening disease? Why is Alzheimer’s disease not only called “the disease that steals human souls”, but also called the “graveyard of companies”? Why has every single approach (which has at most shown only an effect on biomarkers, such as beta amyloid), still failed to show any change in the cognitive decline in patients with this disease? Why have we failed universally, until now?

Because every approach has concentrated on effects, not on causes.

Currently, most approaches target beta amyloid, many target tau proteins, and some target mitochondrial function, inflammation, free radicals, and other processes, but no one targets these problems as a single, unified, overarching process. Alzheimer’s isn’t caused by any one of these disparate processes, but by a broader, more complex process that results in every one of these individual problems. Beta amyloid isn’t a cause, but a biomarker. Equally, tau proteins, phosphodiesterase levels, APOE4, presenilins, and a host of other markers are effects, not causes. The actual cause lies upstream and constitutes the root cause of the dozens of separate effects that are the futile downstream targets of every current FDA trial aimed at Alzheimer’s disease. Understanding this, we will be targeting the “upstream” problem, rather than the dozens of processes that others target individually and without success. Our animal studies support the ability to effectively intervene in human disease: when we say that we are about to cure Alzheimer’s disease, we base claim that on a clear and consistent theoretical model, supported by equally clear and consistent data.

Within the next few months, we will begin our FDA toxicity study, preparatory to obtaining an IND that will permit us to begin our FDA human trial. Our toxicity study will take 6 months and will meet FDA requirements for human safety data. Our first human trial is planned to begin one year from now and is intended to show not only safety, but a clear efficacy. We will include a dozen human volunteers, each with (not just early, but) moderate Alzheimer’s disease and our human trial will last 6 months, including a single treatment and multiple measurements of behavior, laboratory tests, and brain scans. We expect to show unambiguous cognitive improvement within that six-month period. We are confident that we cannot merely slow, not merely stop, but reverse much of the cognitive decline in our twelve patients. We intend to demonstrate an ability to cure Alzheimer’s disease clearly and credibly.

Curing Alzheimer’s requires investments of money, time, and thought. The toxicity study costs 1 million dollars; the human trial costs 2.5 million dollars. Telocyte has half a million dollars committed to this effort and at least one group of investors with a firm interest in taking us all the way through the human trials. We are close and we grow closer each day.

After 110 years, we are about to cure Alzheimer’s.

October 18, 2016

The Carpets of Alzheimer’s Disease

Why do Alzheimer’s interventions always fail?

Whether you ask investors or pharmaceutical companies, it has become axiomatic that Alzheimer’s “has been a graveyard for many a company”, regardless of what they try. But in a fundamental way, all past and all current companies – whether big pharma or small biotech – try the same approach. The problem is that while they work hard at the details, they never examine their premises. They uniformly fail to appreciate the conceptual complexity involved in the pathology of Alzheimer’s. They clearly see the technical complexity, but ignore the deeper complexity. They see the specific molecule and the specific gene, but they ignore the ongoing processes that drive Alzheimer’s. Focusing on a simplistic interpretation of the pathology, they apply themselves – if with admirable dedication and financing – to the specific details, such a beta amyloid deposition.

But WHY do we have beta amyloid deposits? Why do tau proteins tangle, why do mitochondria get sloppy, and why does inflammation occur in the first place? Focusing on outcomes, rather than basic processes explains why all prior efforts have failed to affect the course of the disease, let alone offer a cure for Alzheimer’s.

Let’s use an analogy: think of a maintenance service. Any big organization, (university, pharmaceutical firm, group law practice, or hospital) has a maintenance budget. Routine maintenance ensures that – in the offices, clinics, or laboratories – carpets are vacuumed, walls are repainted, windows are cleaned, floors are mopped, and all the little details are taken care of on a regular basis. These are the details that make a place appear clean and well-cared for, providing a pleasant and healthy location. In most offices (as in our cells), we are often unaware of the maintenance, but quite aware of the end result: an agreeable location to work or visit. In any good workplace, as in our cells, maintenance is efficient and ongoing.

That’s true in young cells, but what happens in old cells?

Imagine what happens to a building if we cut its maintenance budget by 90%. Carpets begin to show dirt, windows become less clear, walls develop nicks and marks, and floors grow grimy and sticky. This is precisely what happens in old cells: we cut back on the maintenance and the result is that cells becomes less functional, because without continual maintenance, damage gradually accumulates. In the nervous system, beta amyloid, tau proteins, and a host of other things “sit around” without being recycled efficiently and quickly. Maintenance is poor and our cells accumulate damage.

All previous Alzheimer’s research has ignored the cut back in maintenance and focused on only a single facet, such as beta amyloid. You might say that they focused only on the dirty carpet and ignored the walls, the windows, and the floors. Even then, they have focused only on the “dirt”, and ignored the cut back in maintenance. Imagine an organization that has cut its maintenance budget. Realizing that they have a problem, they call in an outside specialist to focus exclusively on the loose dirt in the carpet, while ignoring the carpet stains, ignoring the window, walls, and floors, and then only coming in once. What happens? The carpets look better for a few days, but the office still becomes increasingly grungy and unpleasant. In the same way, if we use monoclonal antibodies (the outside specialist) to focus on beta amyloid plaque, the plaques may improve temporarily, but the Alzheimer’s disease continues and it is definitely unpleasant. Various companies have focused on various parts of the problem – the floors, the walls, the windows, or the carpets – but none of them have fixed the maintenance, so the fundamental problem continues. You can put a lot of effort and money into treating only small parts of Alzheimer’s, or you can understand the complex and dynamic nature of cell maintenance. Ironically, once you understand the complexity, the solution becomes simple.

The best solution is to reset cell maintenance to that of younger cells. Neurons and glial cells can again function normally, maintaining themselves and the cells around them. The outcome should be not another “graveyard for companies”, but life beyond Alzheimer’s .

 

February 16, 2016

Unexamined Assumptions

The problem with curing Alzheimer’s is, as with so much of our understanding of aging and age-related diseases, that we make unexamined assumptions. Let me admit that many of our unexamined assumptions are either useful or reasonable. I assume that the sun will come up again tomorrow morning and that’s a useful and reasonable assumption. Useful, in that it allows me to plan my future, reasonable in that the sun has been coming up every morning for quite a while and is therefore likely to do so tomorrow as well. Certain unexamined assumptions are equally justifiable in dealing with Alzheimer’s disease. In the strictly poetic sense, Alzheimer’s certainly is the disease that “steals our souls”, yet no physician or researcher would actually make the assumption that the mind is some vague ethereal quantity that can be stolen by demons, let alone go on to promulgate a theory of Alzheimer’s pathology based on this assumption.

Yet we make exactly that same error, using an unexamined assumption, when we blithely assume that aging is simply the accumulation of damage and, pari passu, that Alzheimer’s disease is simply the accumulation of damaged molecules, be they amyloid, tau tangles, or altered mitochondrial enzymes. This unexamined assumption lies behind almost innumerable multi-million dollar FDA trials, academic papers, and clinical interventions. We assume, without even realizing we have made the assumption, that Alzheimer’s is merely the accumulation of damaged molecules.

We make the same unexamined assumption in looking at other age-related diseases and in the broader field of aging itself. We delve into the details of advanced glycation end-products (AGE), lipofuscin, cross-linking, and other molecular pools showing “accumulative damage”, all the time never realizing that we are making the same fallacy. We are working with completely unexamined (and erroneous) assumptions about how aging works. We naively assume that aging occurs – and age-related diseases follow – merely because things “rust” over time. We age because “molecules fall apart.”

 

Yet the data and logic both say differently. Let me give you a useful analogy: the cell phone. Consider a large pool (several thousand) of people who own cell phones. We know that if we examine any SINGLE cell phone, the best predictor of failure is how long it has been since production. If, however, we want to predict the percentage of failures in any large pool of owners, the best predictor is not time-since-production, but length-of-contract, that is, how often does it get turned over and replaced? Imagine two large pools of cell phone owners. In group A, the cell phones are replaced annually, with a failure rate (at equilibrium) of approximately 1%. In group B, the cell phones are replaced every ten years, with a failure rate (at equilibrium) of approximately 80%. In both groups, the rate of failure of any individual phone is the same. Furthermore, the rate of failure is only marginally related to the “genes”, i.e., whether the phone is an Apple iPhone, an Android, or some other type (a different “allele”). As the turnover rate (contract length to replacement) lengthens, the percent of failed cell phones climbs dramatically, regardless of the failure rate of any individual cell phone. In a pool of cell phones, “aging” is not a matter of passively accumulated damage, but of how actively we replace them.

The same is occurring in molecular pools in biological systems. The key predictor of “denatured” or dysfunctional molecules (e.g., AGE, beta amyloid microaggregates, cross-linking, elastin failure, collagen stiffening, etc) is not the rate of damage but the rate of turnover. In the case of cell aging, when we reset gene expression (reset telomere length) we reset the turnover rates (anabolism and catabolism rates) of all molecular pools to those typical of “young” cells. The outcome is that molecule pool turnover is more than sufficient to deal with typical rates of damage.

Without realizing it, most of us make the mistake of thinking of molecular pools as static and damage as purely accumulative. The reality is that such pools are dynamic and the key dependent variable (as with cell phones) is not the passive rate of damage, but the active rate of turnover.

Unless we understand – and examine – our assumptions, we can never expect to cure age-related diseases. Once we start down the wrong path, all the logic and data in the world can’t make up for the fact that we are looking in the wrong place. It’s time we stopped blaming “demons” and starting thinking carefully.

Older Posts »

Powered by WordPress